BCMA Bispecifics in the Clinic: Data, Toxicities, and Real-World Experience

Talisman Study and Proactive Toxicity Management for Talquetamab
The Talisman trial explores proactive strategies to reduce talquetamab-related toxicities such as dysgeusia and skin effects. Approaches under evaluation include pretreatment with steroids, pregabalin, or clonazepam.

Early data suggest that these interventions may improve tolerability without compromising efficacy. Clinicians have already begun adopting practical dose adjustments, such as reducing dosing frequency to monthly once patients respond.

This study represents a significant step forward in improving patient quality of life while maintaining the therapeutic benefit of bispecifics. Patient-reported outcomes will be central in guiding future dosing recommendations and supportive care practices.